A clinical oncology research team at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), in collaboration with the US National Cancer Institute (NCI), has developed an innovative big data platform, called the ‘Cancer Immunology Data Engine’ (CIDE).
This state-of-the-art platform integrates clinical outcomes from 5,957 cancer patients worldwide who received immunotherapy, along with comprehensive multi-omics datasets covering 17 cancer types and comprising 8,575 tumour samples.
CIDE represents the most extensive database for tumour immunotherapy available to date. Currently publicly accessible via the NCI website (https://cide.ccr.cancer.gov/), the platform enables researchers worldwide to explore and analyse clinical trial data in depth, thereby accelerating advances in cancer immunotherapy research.
Professor Guan Xinyuan, Sophie Y M Chan Professor in Cancer Research and Chair Professor of the Department of Clinical Oncology, Centre of Cancer Medicine, School of Clinical Medicine, HKUMed, together with Dr Jiang Peng of the NCI, highlighted, "We are currently advancing early-phase clinical trials and aim to improve the cure rate for patients with refractory, advanced cancers from the current 5–20% to over 40%. Leveraging the strategic advantages of the Guangdong–Hong Kong–Macao Greater Bay Area, we aim to translate this innovation globally to benefit cancer patients worldwide."
